Cargando…

Entry inhibitors: New advances in HCV treatment

Hepatitis C virus (HCV) infection affects approximately 3% of the world's population and causes chronic liver diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Although current antiviral therapy comprising direct-acting antivirals (DAAs) can achieve a quite satisfying...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Xi-Jing, Zhu, Yong-Zhe, Zhao, Ping, Qi, Zhong-Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735057/ https://www.ncbi.nlm.nih.gov/pubmed/26733381 http://dx.doi.org/10.1038/emi.2016.3

Ejemplares similares

A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes
por: Qian, Xi-Jing, et al.
Publicado: (2016)

Lysosomotropic agents as HCV entry inhibitors
por: Ashfaq, Usman A, et al.
Publicado: (2011)

Targeting HCV Entry For Development of Therapeutics
por: Wong-Staal, Flossie, et al.
Publicado: (2010)

HCV and drug addiction in the historical scenario of infection entry in Italy
por: Massimo, Galli, et al.
Publicado: (2018)

Generation of fluorescent HCV pseudoparticles to study early viral entry events- involvement of Rab1a in HCV entry
por: Bhattacharjee, Chayan, et al.
Publicado: (2022)

HCV entry receptors as potential targets for siRNA-based inhibition of HCV
por: Jahan, Shah, et al.
Publicado: (2011)

New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015)

Endophilin-A2-mediated endocytic pathway is critical for enterovirus 71 entry into caco-2 cells
por: Chen, Sheng-Lin, et al.
Publicado: (2019)

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV
por: Orkin, Chloe, et al.
Publicado: (2022)

A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner
por: Lee, Myungeun, et al.
Publicado: (2017)

Inhibition of HCV 3a genotype entry through Host CD81 and HCV E2 antibodies
por: Ashfaq, Usman A, et al.
Publicado: (2011)

Cyclophilin Inhibitors as a Novel HCV Therapy
por: Tang, Hengli
Publicado: (2010)

Development of global consensus sequence of HCV glycoproteins involved in viral entry
por: Idrees, Sobia, et al.
Publicado: (2013)

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
por: Vogel, Martin, et al.
Publicado: (2009)

Recent advances in the anti-HCV mechanisms of interferon
por: Huang, Menghao, et al.
Publicado: (2014)

HIV-1 Entry, Inhibitors, and Resistance
por: Lobritz, Michael A., et al.
Publicado: (2010)

Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors
por: Walser, Marcel, et al.
Publicado: (2022)

An Efficient New Route to Dihydropyranobenzimidazole Inhibitors of HCV Replication
por: Parker, Matthew A., et al.
Publicado: (2010)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Recent advances in liver transplantation with HCV seropositive donors
por: Murag, Soumya, et al.
Publicado: (2019)

Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study
por: Liu, Qi, et al.
Publicado: (2011)

Advances in the development of entry inhibitors for sialic-acid-targeting viruses
por: Heida, Rick, et al.
Publicado: (2021)

Crabohydrate-Related Inhibitors of Dengue Virus Entry
por: Hidari, Kazuya I.P.J., et al.
Publicado: (2013)

HIV-1 Entry and Membrane Fusion Inhibitors
por: Xiao, Tianshu, et al.
Publicado: (2021)

Small Molecule Inhibitors of Influenza Virus Entry
por: Chen, Zhaoyu, et al.
Publicado: (2021)

The role of HCV proteins on treatment outcomes
por: Kumthip, Kattareeya, et al.
Publicado: (2015)

Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry
por: Rothwangl, Katharina B, et al.
Publicado: (2009)

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin
por: Yang, Jie, et al.
Publicado: (2013)

Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study
por: Fouquet, Baptiste, et al.
Publicado: (2015)

Substituted imidazopyridines as potent inhibitors of HCV replication()
por: Vliegen, Inge, et al.
Publicado: (2009)

Recent Advances in Hepatitis C Virus Cell Entry
por: Bartosch, Birke, et al.
Publicado: (2010)

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo
por: Qian, Xijing, et al.
Publicado: (2022)

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175
por: Gallay, Philippe A., et al.
Publicado: (2016)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

A review on HCV inhibitors: Significance of non-structural polyproteins
por: Ganta, Narayana Murthy, et al.
Publicado: (2019)

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
por: Zhou, Hao, et al.
Publicado: (2022)

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
por: Medvedev, Regina, et al.
Publicado: (2016)

New therapeutic options for HCV in Central Europe
por: Flisiak, Robert, et al.
Publicado: (2016)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l1ck4nffkphp48o6riet439117